{"id":298,"date":"2025-07-11T08:26:06","date_gmt":"2025-07-11T08:26:06","guid":{"rendered":"https:\/\/synonecapital.com\/?post_type=portfolio&#038;p=298"},"modified":"2025-07-13T05:54:27","modified_gmt":"2025-07-13T05:54:27","slug":"academia-sinica-nbrp-venture-studio","status":"publish","type":"portfolio","link":"https:\/\/synonecapital.com\/zh\/portfolio\/academia-sinica-nbrp-venture-studio\/","title":{"rendered":"Academia Sinica\/NBRP Venture Studio"},"content":{"rendered":"\n<div class=\"wp-block-group is-layout-constrained wp-block-group-is-layout-constrained\">\n<h2 class=\"wp-block-heading has-medium-large-font-size\">About<\/h2>\n\n\n\n<p class=\"has-lead-font-size\">In partnership with Prof. Han-Chung Wu of Academia Sinica, we co-established Taiwan\u2019s first venture studio dedicated to early-stage drug discovery within the National Biotechnology Research Park (NBRP). This initiative serves as a specialized incubation platform that systematically transforms academic research into investable biotech ventures.<\/p>\n\n\n\n<p class=\"has-lead-font-size\">The studio integrates Academia Sinica\u2019s strengths in molecular and translational medicine with our expertise in biotech venture formation, building an end-to-end structure encompassing target validation, preclinical strategy, business modeling, and venture team assembly.<\/p>\n\n\n\n<p class=\"has-lead-font-size\">Several startup projects are currently underway, focusing on immuno-oncology, neurodegenerative disorders, and rare diseases, and are in early engagement with global pharmaceutical companies and institutional investors. This collaboration is positioned as a national model for science-to-market transformation, and forms a key component of Academia Sinica\u2019s strategy to accelerate innovation commercialization and international partnerships.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>About In partnership with Prof. Han-Chung Wu of Academi [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":360,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","format":"standard","meta":{"_vp_format_video_url":"","_vp_image_focal_point":[],"footnotes":""},"portfolio_category":[28],"portfolio_tag":[],"class_list":["post-298","portfolio","type-portfolio","status-publish","format-standard","has-post-thumbnail","hentry","portfolio_category-venture-studio"],"_links":{"self":[{"href":"https:\/\/synonecapital.com\/zh\/wp-json\/wp\/v2\/portfolio\/298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/synonecapital.com\/zh\/wp-json\/wp\/v2\/portfolio"}],"about":[{"href":"https:\/\/synonecapital.com\/zh\/wp-json\/wp\/v2\/types\/portfolio"}],"author":[{"embeddable":true,"href":"https:\/\/synonecapital.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/synonecapital.com\/zh\/wp-json\/wp\/v2\/comments?post=298"}],"version-history":[{"count":2,"href":"https:\/\/synonecapital.com\/zh\/wp-json\/wp\/v2\/portfolio\/298\/revisions"}],"predecessor-version":[{"id":315,"href":"https:\/\/synonecapital.com\/zh\/wp-json\/wp\/v2\/portfolio\/298\/revisions\/315"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/synonecapital.com\/zh\/wp-json\/wp\/v2\/media\/360"}],"wp:attachment":[{"href":"https:\/\/synonecapital.com\/zh\/wp-json\/wp\/v2\/media?parent=298"}],"wp:term":[{"taxonomy":"portfolio_category","embeddable":true,"href":"https:\/\/synonecapital.com\/zh\/wp-json\/wp\/v2\/portfolio_category?post=298"},{"taxonomy":"portfolio_tag","embeddable":true,"href":"https:\/\/synonecapital.com\/zh\/wp-json\/wp\/v2\/portfolio_tag?post=298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}